Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2015; 36(01): 17-23
DOI: 10.4103/0971-5851.151773
REVIEW ARTICLE

Impacts of a biobank: Bridging the gap in translational cancer medicine

Tushar Vora
Department of Medical Oncology, Tata Memorial Centre, Parel, Mumbai, Maharashtra, India
,
Nirav Thacker
Department of Medical Oncology, Tata Memorial Centre, Parel, Mumbai, Maharashtra, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

The prevalence of people affected by cancer has been steadily increasing. More and more people are being offered the chance of increased longevity. This has been possible due to advances not only in medicines and techniques but also because of the gain in understanding of cancer biology through Translational Cancer Medicine. A significant step towards obtaining this success was the establishment of successful biobanking practise. In this review we discuss about the importance of a Biobank and the various impacts that a biobank can have not only in the field of cancer but also on many other aspects. Later we discuss a method of quantitative evaluation of these impacts of a biobank.

Keywords

Biobank - impact - translational cancer medicine


Publication History

Article published online:
12 July 2021

© 2015. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
  • 2 Takiar R, Nadayil D, Nandakumar A. Projections of number of cancer cases in India (2010-2020) by cancer groups. Asian Pac J Cancer Prev 2010;11:1045-9.
  • 3 Fontanarosa PB, DeAngelis CD. Basic science and translational research in JAMA. JAMA 2002;287:1728.
  • 4 Sung NS, Crowley WF Jr, Genel M, Salber P, Sandy L, Sherwood LM, et al. Central challenges facing the national clinical research enterprise. JAMA 2003;289:1278-87.
  • 5 Shaw PM, Patterson SD. The value of banked samples for oncology drug discovery and development. J Natl Cancer Inst Monogr 2011;2011:46-9.
  • 6 Oberländer M, Linnebacher M, König A, Bogoevska V, Brodersen C, Kaatz R, et al. The "North German Tumor Bank of Colorectal Cancer": Status report after the first 2 years of support by the German cancer aid foundation. Langenbecks Arch Surg 2013;398:251-8.
  • 7 Hewitt R, Hainaut P. Biobanking in a fast moving world: an international perspective. J Natl Cancer Inst Monogr 2011;2011:50-1.
  • 8 Available from: http://www.training.cancer.gov/includingclinicaltrials/util/print/includingclinicaltrials.pdf. [Last accessed on 2013 Mar].
  • 9 Gurwitz D, Fortier I, Lunshof JE, Knoppers BM. Research ethics. Children and population biobanks. Science 2009;325:818-9.
  • 10 Knoppers BM, Zawati MH, Kirby ES. Sampling populations of humans across the world: ELSI issues. Annu Rev Genomics Hum Genet 2012;13:395-413.
  • 11 Available from: http://www.technopolis-group.com/resources/downloads/life_sciences/1093_BBMRIfinalreport_100921.pdf. [Last accessed on 2013 Mar].
  • 12 Yuille M, van Ommen GJ, Bréchot C, Cambon-Thomsen A, Dagher G, Landegren U, et al. Biobanking for europe. Brief Bioinform 2008;9:14-24.
  • 13 Rogers J, Carolin T, Vaught J, Compton C. Biobankonomics: A taxonomy for evaluating the economic benefits of standardized centralized human biobanking for translational research. J Natl Cancer Inst Monogr 2011;2011:32-8.
  • 14 Zielhuis GA. Biobanking for epidemiology. Public Health 2012;126:214-6.
  • 15 Dall′Olio GM, Bertranpetit J, Wagner A, Laayouni H. Human genome variation and the concept of genotype networks. PLoS One 2014 Jun 9; 9:e99424.
  • 16 Zika E, Paci D, Braun A, Rijkers-Defrasne S, Deschênes M, Fortier I, et al. A European survey on biobanks: Trends and issues. Public Health Genomics 2011;14:96-103.
  • 17 Dawber TR, Kannel WB. An epidemiologic study of heart disease: The Framingham study. Nutr Rev 1958;16:1-4.
  • 18 Kagan A, Dawber TR, kannel WB, Revotskie N. The Framingham study: A prospective study of coronary heart disease. Fed Proc 1962;21:52-7.
  • 19 Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med 1981;141:1128-31.
  • 20 Williams RR, Sorlie PD, Feinleib M, McNamara PM, Kannel WB, Dawber TR. Cancer incidence by levels of cholesterol. JAMA 1981;245:247-52.
  • 21 Tobert JA. New developments in lipid-lowering therapy: The role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation 1987;76:534-8.
  • 22 Wilson PW, Garrison RJ, Abbott RD, Castelli WP. Factors associated with lipoprotein cholesterol levels. The Framingham study. Arteriosclerosis 1983;3:273-81.
  • 23 Available from: http://www.framinghamheartstudy.org/participants/pr/09_1115.html. [Last accessed on 2013 Apr].
  • 24 Collins FS, McKusick VA. Implications of the Human Genome Project for medical science. JAMA 2001;285:540-4.
  • 25 Available from: http://www.ukbiobank.ac.uk/ [Last accessed on 2013 Apr].
  • 26 Linnebacher M, Maletzki C, Ostwald C, Klier U, Krohn M, Klar E, et al. Cryopreservation of human colorectal carcinomas prior to xenografting. BMC Cancer 2010;10:362.
  • 27 Friede A, Grossman R, Hunt R. Biospecimen and data collection and distribution. National Biospecimen Network Blueprint; 2010. Durham, NC: Constella Group Inc; 2003. Available from: http://www.biospecimens.cancer.gov/practices/ [Last accessed on 2013 Jun].
  • 28 Bener J, Konig E. The growing role of biobanking in today′s medical environment. BioProcess Int 2010;8:10-4.
  • 29 Ginsburg GS, Burke TW, Febbo P. Centralized biorepositories for genetic and genomic research. JAMA 2008;299:1359-61.
  • 30 Hens K, Van El CE, Borry P, Cambon-Thomsen A, Cornel MC, Forzano F, et al. Developing a policy for paediatric biobanks: Principles for good practice. Eur J Hum Genet 2013;21:2-7.
  • 31 Available from: http://www.geenivaramu.ee/en/ [Last accessed on 2013 Jun].
  • 32 Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, et al. Emerging concepts in biomarker discovery; the US-Japan workshop on immunological molecular markers in oncology. J Transl Med 2009;7:45.
  • 33 Available from: http://www.ukcrc.org/infrastructure/expmed/fundersvisionforhumantissuesresources/ [Last accessed on 2013 Jun].
  • 34 Fee R. The cost of clinical trials. Drug Discov Dev Mag 2007;10:32. Available from: http://www.dddmagcom/articles/2007/09/cost-clinical-trials. [Last accessed on 2013 Jun].
  • 35 UK National Clinical Research Network Study Portfolio; 2012. Available from: http://www.public.ukcrn.org.uk/search/ [Last accessed on 2013 Jun].
  • 36 Report M. Clincal research in UK-Towards a single system that reliably delivers distinctive quality and rapid access at reasonable cost; 2005. Available from: http://www.ukcrcorg/indexaspx?o=1502. [Last accessed on 2013 Jun].
  • 37 Paik S, Kim CY, Song YK, Kim WS. Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. Nat Clin Pract Oncol 2005;2:246-54.
  • 38 Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004;101:2574-83.
  • 39 Kingsbury K. Time 100 scientists & thinkers. Peter Pronovost. Time 2008;171:86.
  • 40 Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
  • 41 Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001;291:1304-51.
  • 42 Cambon-Thomsen A, Thorisson GA, Mabile L, BRIF Workshop Group. The role of a bioresource research impact factor as an incentive to share human bioresources. Nat Genet 2011;43:503-4.
  • 43 Available from: http://www.gen2phen.org/groups/brif-bio-resource-impact-factor. [Last accessed on 2013 Jun].